epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

MMR II

measles/ mumps/ rubella vaccine, live (MMR)

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  INJ

measles, mumps and rubella prevention

[patients without immunity and with low infection risk]
Dose: 0.5 mL SC/IM x1; Info: for patients with no evidence of immunity or born after 1956; search 'immunization' for epocrates Adult Immunization decision tool including links to CDC/ACIP schedules
[patients without immunity and with high infection risk]
Dose: 0.5 mL SC/IM x2 doses at least 4wk apart; Info: for college students, healthcare workers, international travelers, household or close contacts of immunocompromised patients, and patients with HIV infection and CD4 >200 and >15% for at least 6mo; search 'immunization' for epocrates Adult Immunization decision tool including links to CDC/ACIP schedules

renal dosing

[no adjustment]
renal impairment: no adjustment
HD/PD: no adjustment; no supplement

hepatic dosing

[no adjustment]

Peds Dosing .

Dosage forms:  INJ

measles, mumps and rubella prevention

[6-11 mo (off-label)]
Dose: 0.5 mL SC/IM x1; Info: for international travel-related prophylaxis; give 1 dose before departure; revaccinate at 12-15 mo with 2-dose series at least 4wk apart; search 'immunization' for epocrates Child/Adolescent Immunization decision tool including links to CDC/ACIP schedules
[12 mo and older]
Dose: 0.5 mL SC/IM x1 at 12-15 mo, then 0.5 mL SC/IM x1 at 4-6 yo; Info: may give 2nd dose as early as 4wk after 1st dose; if unvaccinated and traveling internationally, give 2-dose series at least 4wk apart before departure; search 'immunization' for epocrates Child/Adolescent Immunization decision tool including links to CDC/ACIP schedules

renal dosing

[no adjustment]
renal impairment: no adjustment
HD/PD: no adjustment; no supplement

hepatic dosing

[no adjustment]

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@244d9666
  • hypersensitivity to drug or ingredient
  • hypersensitivity to gelatin
  • pregnancy
  • immunocompromised patients
  • HIV infection with CD4 <15%
  • HIV infection with CD4 <200
  • TB infection, active untreated
  • febrile illness, acute
  • caution: antibody-containing blood product use, recent
  • caution: hypersensitivity to egg
  • caution: hypersensitivity to neomycin
  • caution: patients of childbearing potential
  • caution: seizure history
  • caution: seizures family history
  • caution: thrombocytopenia
  • caution: TB infection risk
  • caution: illness, acute moderate-severe

Drug Interactions .

Overview

measles/mumps/rubella vaccine, live

live vaccine

Interaction Characteristics:
  • live vaccine

Contraindicated

  • abatacept
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    abatacept
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + abatacept

    contraindicated; vaccinate at least 4wk before or 3mo after abatacept tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • abemaciclib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    abemaciclib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + abemaciclib

    contraindicated; vaccinate at least 4wk before or 3mo after abemaciclib use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • abrocitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    abrocitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + abrocitinib

    contraindicated; vaccinate at least 4wk before or 3mo after abrocitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • acalabrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    acalabrutinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + acalabrutinib

    contraindicated; vaccinate at least 4wk before or 3mo after acalabrutinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • adalimumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    adalimumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + adalimumab

    contraindicated; vaccinate at least 4wk before or 3mo after adalimumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • afamitresgene autoleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    afamitresgene autoleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + afamitresgene autoleucel

    contraindicated; vaccinate at least 4wk before or 3mo after afamitresgene autoleucel tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • aldesleukin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    aldesleukin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + aldesleukin

    contraindicated; vaccinate at least 4wk before or 3mo after aldesleukin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • alemtuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    alemtuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + alemtuzumab

    contraindicated; vaccinate at least 6wk before or 6mo after alemtuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • amivantamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    amivantamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + amivantamab

    contraindicated; vaccinate at least 4wk before or 3mo after amivantamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • anakinra
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    anakinra
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + anakinra

    contraindicated; vaccinate at least 4wk before or 3mo after anakinra tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • anifrolumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    anifrolumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + anifrolumab

    contraindicated; vaccinate at least 4wk before or 3mo after anifrolumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • anti-thymocyte globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    anti-thymocyte globulin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + anti-thymocyte globulin

    contraindicated; vaccinate at least 4wk before or 3mo after anti-thymocyte globulin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • asciminib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    asciminib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + asciminib

    contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • atezolizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    atezolizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + atezolizumab

    contraindicated; vaccinate at least 4wk before or 3-6mo after atezolizumab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • atidarsagene autotemcel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    atidarsagene autotemcel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + atidarsagene autotemcel

    contraindicated; vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • avelumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    avelumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + avelumab

    contraindicated; vaccinate at least 4wk before or 3mo after avelumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • axicabtagene ciloleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    axicabtagene ciloleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + axicabtagene ciloleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • azacitidine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    azacitidine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + azacitidine

    contraindicated; vaccinate at least 4wk before or 3mo after azacitidine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • azathioprine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    azathioprine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + azathioprine

    contraindicated; vaccinate at least 4wk before or 3mo after azathioprine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • baricitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    baricitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + baricitinib

    contraindicated; vaccinate at least 4wk before or 3mo after baricitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • basiliximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    basiliximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + basiliximab

    contraindicated; vaccinate at least 4wk before or 3mo after basiliximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • belantamab mafodotin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    belantamab mafodotin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + belantamab mafodotin

    contraindicated; vaccinate at least 4wk before or 6mo after belantamab mafodotin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • belatacept
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    belatacept
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + belatacept

    contraindicated; vaccinate at least 4wk before or 3mo after belatacept tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • belimumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    belimumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + belimumab

    contraindicated; vaccinate at least 30 days before or 6mo after belimumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • belinostat
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    belinostat
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + belinostat

    contraindicated; vaccinate at least 4wk before or 3mo after belinostat tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • bendamustine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    bendamustine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + bendamustine

    contraindicated; vaccinate at least 4wk before or 3mo after bendamustine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • betamethasone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    betamethasone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + betamethasone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • bimekizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    bimekizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + bimekizumab

    contraindicated; vaccinate at least 4wk before or 3mo after bimekizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • blinatumomab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    blinatumomab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + blinatumomab

    contraindicated; vaccinate at least 4wk before or 6mo after blinatumomab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • bortezomib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    bortezomib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + bortezomib

    contraindicated; vaccinate at least 4wk before or 3mo after bortezomib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • brensocatib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    brensocatib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + brensocatib

    contraindicated; vaccinate at least 4wk before or 3mo after brensocatib: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • brentuximab vedotin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    brentuximab vedotin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + brentuximab vedotin

    contraindicated; vaccinate at least 4wk before or 6mo after brentuximab vedotin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • brexucabtagene autoleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    brexucabtagene autoleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + brexucabtagene autoleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • brodalumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    brodalumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + brodalumab

    contraindicated; vaccinate at least 4wk before or 3mo after brodalumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • budesonide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    budesonide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + budesonide

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • busulfan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    busulfan
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + busulfan

    contraindicated; vaccinate at least 4wk before or 3mo after busulfan use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cabazitaxel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cabazitaxel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cabazitaxel

    contraindicated; vaccinate at least 4wk before or 3mo after cabazitaxel tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • canakinumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    canakinumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + canakinumab

    contraindicated; vaccinate at least 4wk before or 3mo after canakinumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • capecitabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    capecitabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + capecitabine

    contraindicated; vaccinate at least 4wk before or 3mo after capecitabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • carboplatin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    carboplatin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + carboplatin

    contraindicated; vaccinate at least 4wk before or 3mo after carboplatin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • carfilzomib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    carfilzomib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + carfilzomib

    contraindicated; vaccinate at least 4wk before or 3mo after carfilzomib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • carmustine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    carmustine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + carmustine

    contraindicated; vaccinate at least 4wk before or 3mo after carmustine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cemiplimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cemiplimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cemiplimab

    contraindicated; vaccinate at least 4wk before or 3-6mo after cemiplimab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • certolizumab pegol
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    certolizumab pegol
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + certolizumab pegol

    contraindicated; vaccinate at least 4wk before or 3mo after certolizumab pegol tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • chlorambucil
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    chlorambucil
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + chlorambucil

    contraindicated; vaccinate at least 4wk before or 3mo after chlorambucil tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ciltacabtagene autoleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ciltacabtagene autoleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ciltacabtagene autoleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cisplatin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cisplatin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cisplatin

    contraindicated; vaccinate at least 4wk before or 3mo after cisplatin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cladribine injection
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cladribine injection
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cladribine injection

    contraindicated; vaccinate at least 4wk before or 3mo after cladribine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cladribine oral
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cladribine oral
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cladribine oral

    contraindicated; vaccinate at least 4wk before or 3mo after cladribine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • clofarabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    clofarabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + clofarabine

    contraindicated; vaccinate at least 4wk before or 3mo after clofarabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • copanlisib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    copanlisib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + copanlisib

    contraindicated; vaccinate at least 4wk before or 3mo after copanlisib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • corticotropin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    corticotropin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + corticotropin

    contraindicated; vaccinate at least 4wk before or 3mo after corticotropin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cortisone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cortisone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cortisone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cosibelimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cosibelimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cosibelimab

    contraindicated; vaccinate at least 4wk before or 3mo after cosibelimab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cyclophosphamide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cyclophosphamide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cyclophosphamide

    contraindicated; vaccinate at least 4wk before or 3mo after cyclophosphamide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cyclosporine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cyclosporine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cyclosporine

    contraindicated; vaccinate at least 4wk before or 3mo after cyclosporine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cytarabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cytarabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + cytarabine

    contraindicated; vaccinate at least 4wk before or 3mo after cytarabine use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dactinomycin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dactinomycin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dactinomycin

    contraindicated; vaccinate at least 4wk before or 3mo after dactinomycin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • daratumumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    daratumumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + daratumumab

    contraindicated; vaccinate at least 4wk before or 6mo after daratumumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dasatinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dasatinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dasatinib

    contraindicated; vaccinate at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • daunorubicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    daunorubicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + daunorubicin

    contraindicated; vaccinate at least 4wk before or 3mo after daunorubicin use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • decitabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    decitabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + decitabine

    contraindicated; vaccinate at least 4wk before or 3mo after decitabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • deflazacort
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    deflazacort
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + deflazacort

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • delgocitinib topical
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    delgocitinib topical
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + delgocitinib topical

    contraindicated; vaccinate at least 4wk before or 3mo after delgocitinib topical tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • deucravacitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    deucravacitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + deucravacitinib

    contraindicated; vaccinate at least 4wk before or 3mo after deucravacitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • deuruxolitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    deuruxolitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + deuruxolitinib

    contraindicated; vaccinate at least 4wk before or 3mo after deuruxolitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dexamethasone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dexamethasone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dexamethasone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dimethyl fumarate
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dimethyl fumarate
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dimethyl fumarate

    contraindicated; vaccinate at least 4wk before or 3mo after dimethyl fumarate tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dinutuximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dinutuximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dinutuximab

    contraindicated; vaccinate at least 4wk before or 3mo after dinutuximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • diroximel fumarate
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    diroximel fumarate
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + diroximel fumarate

    contraindicated; vaccinate at least 4wk before or 3mo after diroximel fumarate tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • docetaxel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    docetaxel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + docetaxel

    contraindicated; vaccinate at least 4wk before or 3mo after docetaxel tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dostarlimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dostarlimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dostarlimab

    contraindicated; vaccinate at least 4wk before or 3-6mo after dostarlimab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • doxorubicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    doxorubicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + doxorubicin

    contraindicated; vaccinate at least 4wk before or 3mo after doxorubicin use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dupilumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dupilumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + dupilumab

    contraindicated; vaccinate at least 4wk before or 3mo after dupilumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • durvalumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    durvalumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + durvalumab

    contraindicated; vaccinate at least 4wk before or 3mo after durvalumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • duvelisib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    duvelisib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + duvelisib

    contraindicated; vaccinate at least 4wk before or 3mo after duvelisib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • efgartigimod alfa
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    efgartigimod alfa
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + efgartigimod alfa

    contraindicated; vaccinate at least 4wk before or 3mo after efgartigimod alfa tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • elivaldogene autotemcel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    elivaldogene autotemcel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + elivaldogene autotemcel

    contraindicated; vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • elotuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    elotuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + elotuzumab

    contraindicated; vaccinate at least 4wk before or 3mo after elotuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • elranatamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    elranatamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + elranatamab

    contraindicated; vaccinate at least 4wk before or 6mo after elranatamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • emapalumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    emapalumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + emapalumab

    contraindicated; vaccinate at least 4wk before or 3mo after emapalumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • epcoritamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    epcoritamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + epcoritamab

    contraindicated; vaccinate at least 4wk before or 6mo after epcoritamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • epirubicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    epirubicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + epirubicin

    contraindicated; vaccinate at least 4wk before or 3mo after epirubicin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • erdafitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    erdafitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + erdafitinib

    contraindicated; vaccinate at least 4wk before or 3mo after erdafitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • eribulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    eribulin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + eribulin

    contraindicated; vaccinate at least 4wk before or 3mo after eribulin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • etanercept
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    etanercept
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + etanercept

    contraindicated; vaccinate at least 4wk before or 3mo after etanercept tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • etoposide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    etoposide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + etoposide

    contraindicated; vaccinate at least 4wk before or 3mo after etoposide use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • etrasimod
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    etrasimod
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + etrasimod

    contraindicated; vaccinate at least 1mo before or 3mo after etrasimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • etuvetidigene autotemcel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    etuvetidigene autotemcel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + etuvetidigene autotemcel

    contraindicated; vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • everolimus
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    everolimus
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + everolimus

    contraindicated; vaccinate at least 4wk before or 3mo after everolimus tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fingolimod
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fingolimod
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + fingolimod

    contraindicated; vaccinate at least 4wk before or 3mo after fingolimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • floxuridine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    floxuridine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + floxuridine

    contraindicated; vaccinate at least 4wk before or 3mo after floxuridine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fludarabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fludarabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + fludarabine

    contraindicated; vaccinate at least 4wk before or 3mo after fludarabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fludrocortisone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fludrocortisone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + fludrocortisone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fluorouracil
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fluorouracil
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + fluorouracil

    contraindicated; vaccinate at least 4wk before or 3mo after fluorouracil use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fruquintinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fruquintinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + fruquintinib

    contraindicated; vaccinate at least 4wk before or 3mo after fruquintinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • futibatinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    futibatinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + futibatinib

    contraindicated; vaccinate at least 4wk before or 3mo after futibatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • gemcitabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    gemcitabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + gemcitabine

    contraindicated; vaccinate at least 4wk before or 3mo after gemcitabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • gemtuzumab ozogamicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    gemtuzumab ozogamicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + gemtuzumab ozogamicin

    contraindicated; vaccinate at least 4wk before or 3mo after gemtuzumab ozogamicin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • glofitamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    glofitamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + glofitamab

    contraindicated; vaccinate at least 4wk before or 6mo after glofitamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • golimumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    golimumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + golimumab

    contraindicated; vaccinate at least 4wk before or 3mo after golimumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • guselkumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    guselkumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + guselkumab

    contraindicated; vaccinate at least 4wk before or 3mo after guselkumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • hydrocortisone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    hydrocortisone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + hydrocortisone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • hydroxyurea
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    hydroxyurea
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + hydroxyurea

    contraindicated; vaccinate at least 4wk before or 3mo after hydroxyurea tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ibritumomab tiuxetan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ibritumomab tiuxetan
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ibritumomab tiuxetan

    contraindicated; vaccinate at least 4wk before or 12mo after ibritumomab tiuxetan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ibrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ibrutinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ibrutinib

    contraindicated; vaccinate at least 4wk before or 3mo after ibrutinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • icotrokinra
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    icotrokinra
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + icotrokinra

    contraindicated; vaccinate at least 4wk before or 3mo after icotrokinra use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • idarubicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    idarubicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + idarubicin

    contraindicated; vaccinate at least 4wk before or 3mo after idarubicin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • idecabtagene vicleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    idecabtagene vicleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + idecabtagene vicleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • idelalisib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    idelalisib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + idelalisib

    contraindicated; vaccinate at least 4wk before or 3mo after idelalisib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ifosfamide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ifosfamide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ifosfamide

    contraindicated; vaccinate at least 4wk before or 3mo after ifosfamide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • imatinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    imatinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + imatinib

    contraindicated; vaccinate at least 4wk before or 3mo after imatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • inebilizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    inebilizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + inebilizumab

    contraindicated; vaccinate at least 4wk before or 6mo after inebilizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • infliximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    infliximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + infliximab

    contraindicated; vaccinate at least 4wk before or 3mo after infliximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • inotuzumab ozogamicin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    inotuzumab ozogamicin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + inotuzumab ozogamicin

    contraindicated; vaccinate at least 4wk before or 6mo after inotuzumab ozogamicin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ipilimumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ipilimumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ipilimumab

    contraindicated; vaccinate at least 4wk before or 3mo after ipilimumab: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • irinotecan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    irinotecan
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + irinotecan

    contraindicated; vaccinate at least 4wk before or 3mo after irinotecan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • isatuximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    isatuximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + isatuximab

    contraindicated; vaccinate at least 4wk before or 6mo after isatuximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ixabepilone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ixabepilone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ixabepilone

    contraindicated; vaccinate at least 4wk before or 3mo after ixabepilone tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ixekizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ixekizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ixekizumab

    contraindicated; vaccinate at least 4wk before or 3mo after ixekizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lazertinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lazertinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lazertinib

    contraindicated; vaccinate at least 4wk before or 3mo after lazertinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lebrikizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lebrikizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lebrikizumab

    contraindicated; vaccinate at least 4wk before or 3mo after lebrikizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • leflunomide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    leflunomide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + leflunomide

    contraindicated; vaccinate at least 4wk before or 6mo after leflunomide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lenalidomide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lenalidomide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lenalidomide

    contraindicated; vaccinate at least 4wk before or 3mo after lenalidomide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • linvoseltamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    linvoseltamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + linvoseltamab

    contraindicated; vaccinate at least 4wk before or 6mo after linvoseltamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lisocabtagene maraleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lisocabtagene maraleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lisocabtagene maraleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lomustine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lomustine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lomustine

    contraindicated; vaccinate at least 4wk before or 3mo after lomustine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • loncastuximab tesirine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    loncastuximab tesirine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + loncastuximab tesirine

    contraindicated; vaccinate at least 4wk before or 6mo after loncastuximab tesirine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + lymphocyte immune globulin, anti-thymocyte globulin

    contraindicated; vaccinate at least 4wk before or 3mo after anti-thymocyte globulin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • marnetegragene autotemcel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    marnetegragene autotemcel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + marnetegragene autotemcel

    contraindicated; vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • melphalan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    melphalan
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + melphalan

    contraindicated; vaccinate at least 4wk before or 3mo after melphalan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mercaptopurine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mercaptopurine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mercaptopurine

    contraindicated; vaccinate at least 4wk before or 3mo after mercaptopurine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • methylprednisolone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    methylprednisolone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + methylprednisolone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mirikizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mirikizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mirikizumab

    contraindicated; vaccinate at least 4wk before or 3mo after mirikizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mitoxantrone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mitoxantrone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mitoxantrone

    contraindicated; vaccinate at least 4wk before or 3mo after mitoxantrone tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mogamulizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mogamulizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mogamulizumab

    contraindicated; vaccinate at least 4wk before or 3mo after mogamulizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • momelotinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    momelotinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + momelotinib

    contraindicated; vaccinate at least 4wk before or 3mo after momelotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • monomethyl fumarate
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    monomethyl fumarate
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + monomethyl fumarate

    contraindicated; vaccinate at least 4wk before or 3mo after monomethyl fumarate tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mosunetuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mosunetuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mosunetuzumab

    contraindicated; vaccinate at least 4wk before or 6mo after mosunetuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mycophenolate mofetil
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mycophenolate mofetil
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mycophenolate mofetil

    contraindicated; vaccinate at least 4wk before or 3mo after mycophenolate mofetil tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mycophenolic acid
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mycophenolic acid
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + mycophenolic acid

    contraindicated; vaccinate at least 4wk before or 3mo after mycophenolic acid tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • natalizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    natalizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + natalizumab

    contraindicated; vaccinate at least 4wk before or 3mo after natalizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • nelarabine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    nelarabine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + nelarabine

    contraindicated; vaccinate at least 4wk before or 3mo after nelarabine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • nemolizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    nemolizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + nemolizumab

    contraindicated; vaccinate at least 4wk before or 3mo after nemolizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • nipocalimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    nipocalimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + nipocalimab

    contraindicated; vaccinate at least 4wk before or 3mo after nipocalimab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • nivolumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    nivolumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + nivolumab

    contraindicated; vaccinate at least 4wk before or 3mo after nivolumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • obinutuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    obinutuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + obinutuzumab

    contraindicated; vaccinate at least 4wk before or 6mo after obinutuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ocrelizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ocrelizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ocrelizumab

    contraindicated; vaccinate at least 4wk before or 6mo after ocrelizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ofatumumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ofatumumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ofatumumab

    contraindicated; vaccinate at least 4wk before or 6mo after ofatumumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • oxaliplatin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    oxaliplatin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + oxaliplatin

    contraindicated; vaccinate at least 4wk before or 3mo after oxaliplatin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ozanimod
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ozanimod
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ozanimod

    contraindicated; vaccinate at least 1mo before or 3mo after ozanimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • paclitaxel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    paclitaxel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + paclitaxel

    contraindicated; vaccinate at least 4wk before or 3mo after paclitaxel tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • palbociclib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    palbociclib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + palbociclib

    contraindicated; vaccinate at least 4wk before or 3mo after palbociclib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • peginterferon alfa 2a
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    peginterferon alfa 2a
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + peginterferon alfa 2a

    contraindicated; vaccinate at least 4wk before or 3-6mo after peginterferon alfa 2a tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pembrolizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pembrolizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pembrolizumab

    contraindicated; vaccinate at least 4wk before or 3mo after pembrolizumab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pemetrexed
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pemetrexed
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pemetrexed

    contraindicated; vaccinate at least 4wk before or 3mo after pemetrexed: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • penpulimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    penpulimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + penpulimab

    contraindicated; vaccinate at least 4wk before or 3-6mo after penpulimab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pentostatin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pentostatin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pentostatin

    contraindicated; vaccinate at least 4wk before or 3mo after pentostatin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pertuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pertuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pertuzumab

    contraindicated; vaccinate at least 4wk before or 3mo after pertuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pirtobrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pirtobrutinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pirtobrutinib

    contraindicated; vaccinate at least 4wk before or 3mo after pirtobrutinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • polatuzumab vedotin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    polatuzumab vedotin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + polatuzumab vedotin

    contraindicated; vaccinate at least 4wk before or 6mo after polatuzumab vedotin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • pomalidomide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    pomalidomide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + pomalidomide

    contraindicated; vaccinate at least 4wk before or 3mo after pomalidomide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ponatinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ponatinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ponatinib

    contraindicated; vaccinate at least 4wk before or 3mo after ponatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ponesimod
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ponesimod
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ponesimod

    contraindicated; vaccinate at least 1mo before or 3mo after ponesimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • prednisolone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    prednisolone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + prednisolone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • prednisone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    prednisone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + prednisone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • procarbazine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    procarbazine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + procarbazine

    contraindicated; vaccinate at least 4wk before or 3mo after procarbazine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • quizartinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    quizartinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + quizartinib

    contraindicated; vaccinate at least 4wk before or 3mo after quizartinib use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • regorafenib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    regorafenib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + regorafenib

    contraindicated; vaccinate at least 4wk before or 3mo after regorafenib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • relacorilant
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    relacorilant
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + relacorilant

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • retifanlimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    retifanlimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + retifanlimab

    contraindicated; vaccinate at least 4wk before or 3-6mo after retifanlimab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • revumenib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    revumenib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + revumenib

    contraindicated; vaccinate at least 4wk before or 3mo after revumenib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rilonacept
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rilonacept
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + rilonacept

    contraindicated; vaccinate at least 4wk before or 3mo after rilonacept tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rilzabrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rilzabrutinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + rilzabrutinib

    contraindicated; vaccinate at least 4wk before or 6mo after rilzabrutinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • risankizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    risankizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + risankizumab

    contraindicated; vaccinate at least 4wk before or 3mo after risankizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ritlecitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ritlecitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ritlecitinib

    contraindicated; vaccinate at least 4wk before or 3mo after ritlecitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rituximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rituximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + rituximab

    contraindicated; vaccinate at least 4wk before or 6mo after rituximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • romidepsin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    romidepsin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + romidepsin

    contraindicated; vaccinate at least 4wk before or 3mo after romidepsin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ropeginterferon alfa-2b
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ropeginterferon alfa-2b
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ropeginterferon alfa-2b

    contraindicated; vaccinate at least 4wk before or 3mo after ropeginterferon alfa-2b tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rozanolixizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rozanolixizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + rozanolixizumab

    contraindicated; vaccinate at least 4wk before or 3mo after rozanolixizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rucaparib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rucaparib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + rucaparib

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • ruxolitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ruxolitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ruxolitinib

    contraindicated; vaccinate at least 4wk before or 3mo after ruxolitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sarilumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sarilumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sarilumab

    contraindicated; vaccinate at least 4wk before or 3mo after sarilumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • satralizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    satralizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + satralizumab

    contraindicated; vaccinate at least 4wk before or 3mo after satralizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • secukinumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    secukinumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + secukinumab

    contraindicated; vaccinate at least 4wk before or 3mo after secukinumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • selinexor
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    selinexor
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + selinexor

    contraindicated; vaccinate at least 4wk before or 3mo after selinexor tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • selumetinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    selumetinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + selumetinib

    contraindicated; vaccinate at least 4wk before or 3mo after selumetinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sevabertinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sevabertinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sevabertinib

    contraindicated; vaccinate at least 4wk before or 3mo after sevabertinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sibeprenlimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sibeprenlimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sibeprenlimab

    contraindicated; vaccinate at least 4wk before or 6mo after sibeprenlimab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • siltuximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    siltuximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + siltuximab

    contraindicated; vaccinate at least 4wk before or 3mo after siltuximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • siponimod
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    siponimod
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + siponimod

    contraindicated; vaccinate at least 4wk before or 3mo after siponimod tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sirolimus
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sirolimus
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sirolimus

    contraindicated; vaccinate at least 4wk before or 3mo after sirolimus tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sirolimus albumin-bound
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sirolimus albumin-bound
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sirolimus albumin-bound

    contraindicated; vaccinate at least 4wk before or 3mo after sirolimus albumin-bound tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sirolimus topical
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sirolimus topical
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sirolimus topical

    contraindicated; vaccinate at least 4wk before or 3mo after sirolimus tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sonrotoclax
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sonrotoclax
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sonrotoclax

    contraindicated; vaccinate at least 4wk before or 6mo after sonrotoclax use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sorafenib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sorafenib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sorafenib

    contraindicated; vaccinate at least 4wk before or 3mo after sorafenib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • spesolimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    spesolimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + spesolimab

    contraindicated; vaccinate at least 4wk before or 16wk after spesolimab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sunitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sunitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + sunitinib

    contraindicated; vaccinate at least 4wk before or 3mo after sunitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tacrolimus
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tacrolimus
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tacrolimus

    contraindicated; vaccinate at least 4wk before or 3mo after tacrolimus tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tafasitamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tafasitamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tafasitamab

    contraindicated; vaccinate at least 4wk before or 6mo after tafasitamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • taletrectinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    taletrectinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + taletrectinib

    contraindicated; vaccinate at least 4wk before or 3mo after taletrectinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • talquetamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    talquetamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + talquetamab

    contraindicated; vaccinate at least 4wk before or 6mo after talquetamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tarlatamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tarlatamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tarlatamab

    contraindicated; vaccinate at least 4wk before or 3mo after tarlatamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • teclistamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    teclistamab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + teclistamab

    contraindicated; vaccinate at least 4wk before or 6mo after teclistamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • temozolomide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    temozolomide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + temozolomide

    contraindicated; vaccinate at least 4wk before or 3mo after temozolomide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • temsirolimus
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    temsirolimus
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + temsirolimus

    contraindicated; vaccinate at least 4wk before or 3mo after temsirolimus use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • teplizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    teplizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + teplizumab

    contraindicated; vaccinate at least 8wk before or 52wk after teplizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • teriflunomide
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    teriflunomide
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + teriflunomide

    contraindicated; vaccinate at least 4wk before or 6mo after teriflunomide tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • thioguanine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    thioguanine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + thioguanine

    contraindicated; vaccinate at least 4wk before or 3mo after thioguanine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • thiotepa
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    thiotepa
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + thiotepa

    contraindicated; vaccinate at least 4wk before or 3mo after thiotepa tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tildrakizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tildrakizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tildrakizumab

    contraindicated; vaccinate at least 4wk before or 3mo after tildrakizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tisagenlecleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tisagenlecleucel
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tisagenlecleucel

    contraindicated; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tislelizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tislelizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tislelizumab

    contraindicated; vaccinate at least 4wk before or 3-6mo after tislelizumab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tocilizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tocilizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tocilizumab

    contraindicated; vaccinate at least 4wk before or 3mo after tocilizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tofacitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tofacitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tofacitinib

    contraindicated; vaccinate at least 4wk before or 3mo after tofacitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • topotecan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    topotecan
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + topotecan

    contraindicated; vaccinate at least 4wk before or 3mo after topotecan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • toripalimab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    toripalimab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + toripalimab

    contraindicated; vaccinate at least 4wk before or 3-6mo after toripalimab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • trabectedin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    trabectedin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + trabectedin

    contraindicated; vaccinate at least 4wk before or 3mo after trabectedin: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tralokinumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tralokinumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tralokinumab

    contraindicated; vaccinate at least 4wk before or 3mo after tralokinumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • trastuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    trastuzumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + trastuzumab

    contraindicated; vaccinate at least 4wk before or 3mo after trastuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tremelimumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tremelimumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + tremelimumab

    contraindicated; vaccinate at least 4wk before or 3-6mo after tremelimumab tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • triamcinolone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    triamcinolone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + triamcinolone

    contraindicated; vaccinate at least 1mo before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ublituximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ublituximab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ublituximab

    contraindicated; vaccinate at least 4wk before or 6mo after ublituximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • upadacitinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    upadacitinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + upadacitinib

    contraindicated; vaccinate at least 4wk before or 3mo after upadacitinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ustekinumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ustekinumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ustekinumab

    contraindicated; vaccinate at least 4wk before or 3mo after ustekinumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • vamorolone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vamorolone
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + vamorolone

    contraindicated; vaccinate at least 6wk before or 1mo after long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • vedolizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vedolizumab
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + vedolizumab

    contraindicated; vaccinate at least 4wk before or 3mo after vedolizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • venetoclax
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    venetoclax
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + venetoclax

    contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • vinblastine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vinblastine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + vinblastine

    contraindicated; vaccinate at least 4wk before or 3mo after vinblastine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • vincristine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vincristine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + vincristine

    contraindicated; vaccinate at least 4wk before or 3mo after vincristine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • vinorelbine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vinorelbine
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + vinorelbine

    contraindicated; vaccinate at least 4wk before or 3mo after vinorelbine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • voclosporin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    voclosporin
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + voclosporin

    contraindicated; vaccinate at least 4wk before or 3mo after voclosporin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • zanubrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    zanubrutinib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + zanubrutinib

    contraindicated; vaccinate at least 4wk before or 3mo after zanubrutinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ziftomenib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ziftomenib
    1 interaction

    Contraindicated

    measles/ mumps/ rubella vaccine, live + ziftomenib

    contraindicated; vaccinate at least 4wk before or 3mo after ziftomenib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

  • ado-trastuzumab emtansine
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ado-trastuzumab emtansine
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + ado-trastuzumab emtansine

    avoid combo; vaccinate at least 4wk before or 3-6mo after ado-trastuzumab emtansine tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • avutometinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    avutometinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + avutometinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after avutometinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • belzutifan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    belzutifan
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + belzutifan

    avoid combo; vaccinate at least 4wk before or 3-6mo after belzutifan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • bevacizumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    bevacizumab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + bevacizumab

    avoid combo; vaccinate at least 4wk before or 3-6mo after bevacizumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • capmatinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    capmatinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + capmatinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after capmatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cetuximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cetuximab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + cetuximab

    avoid combo; vaccinate at least 4wk before or 3-6mo after cetuximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • defactinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    defactinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + defactinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after defactinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dordaviprone
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dordaviprone
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + dordaviprone

    avoid combo; vaccinate at least 4wk before or 3-6mo after dordaviprone: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • fam-trastuzumab deruxtecan
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    fam-trastuzumab deruxtecan
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + fam-trastuzumab deruxtecan

    avoid combo; vaccinate at least 4wk before or 3-6mo after fam-trastuzumab deruxtecan tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • interferon gamma 1b
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    interferon gamma 1b
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + interferon gamma 1b

    avoid combo: combo may result in amplified immune response (immunomodulatory effects)

  • lurbinectedin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    lurbinectedin
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + lurbinectedin

    avoid combo; vaccinate at least 4wk before or 3-6mo after lurbinectedin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • margetuximab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    margetuximab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + margetuximab

    avoid combo; vaccinate at least 4wk before or 3-6mo after margetuximab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • methotrexate
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    methotrexate
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + methotrexate

    avoid combo; vaccinate at least 4wk before or 3-6mo after methotrexate tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • mitomycin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    mitomycin
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + mitomycin

    avoid combo; vaccinate at least 4wk before or 3-6mo after mitomycin: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • nilotinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    nilotinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + nilotinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • obecabtagene autoleucel
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    obecabtagene autoleucel
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + obecabtagene autoleucel

    avoid combo; vaccinate at least 6wk before lymphodepleting chemotherapy or after immune recovery: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • olaparib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    olaparib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + olaparib

    avoid combo; vaccinate at least 4wk before or 3-6mo after olaparib: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • panitumumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    panitumumab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + panitumumab

    avoid combo; vaccinate at least 4wk before or 3-6mo after panitumumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • remibrutinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    remibrutinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + remibrutinib

    avoid combo; vaccinate at least 4wk before or 3mo after remibrutinib: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ripretinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ripretinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + ripretinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after ripretinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • sunvozertinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    sunvozertinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + sunvozertinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after sunvozertinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • telisotuzumab vedotin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    telisotuzumab vedotin
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + telisotuzumab vedotin

    avoid combo; vaccinate at least 4wk before or 3-6mo after telisotuzumab vedotin tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • tezepelumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tezepelumab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + tezepelumab

    avoid combo; consider vaccinating at least 4wk before or 3mo after tezepelumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (possible immunosuppressive effects)

  • vandetanib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + vandetanib

    avoid combo; vaccinate at least 4wk before or 3-6mo after vandetanib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • zanidatamab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    zanidatamab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + zanidatamab

    avoid combo; vaccinate at least 4wk before or 3-6mo after zanidatamab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • zenocutuzumab
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    zenocutuzumab
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + zenocutuzumab

    avoid combo; vaccinate at least 4wk before or 3-6mo after zenocutuzumab tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • zongertinib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    zongertinib
    1 interaction

    Avoid/Use Alternative

    measles/ mumps/ rubella vaccine, live + zongertinib

    avoid combo; vaccinate at least 4wk before or 3-6mo after zongertinib: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Monitor/Modify Tx

  • anthrax immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    anthrax immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + anthrax immune globulin

    vaccinate at least 2wk before or 3mo after anthrax immune globulin tx; if vaccine given shortly before anthrax immune globulin, consider re-vaccination at least 3mo after anthrax immune globulin: combo may result in inadequate vaccine response (antagonistic effects)

  • botulism immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    botulism immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + botulism immune globulin

    vaccinate at least 2wk before or 6mo after botulism immune globulin tx; if measles/mumps/rubella vaccine given shortly before botulism immune globulin, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • budesonide rectal
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    budesonide rectal
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + budesonide rectal

    consider vaccinating at least 1mo before or 1mo after budesonide rectal use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • chikungunya vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    chikungunya vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + chikungunya vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • cytomegalovirus immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    cytomegalovirus immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + cytomegalovirus immune globulin

    vaccinate at least 2wk before or 6mo after cytomegalovirus immune globulin tx; if vaccine given shortly before cytomegalovirus immune globulin, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • dengue vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    dengue vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + dengue vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • ebola vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    ebola vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + ebola vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • glatiramer
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    glatiramer
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + glatiramer

    consider vaccinating 4wk before or 3-6mo after glatiramer tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • hepatitis B immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    hepatitis B immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + hepatitis B immune globulin

    vaccinate at least 2wk before or 3mo after hepatitis B immune globulin tx; if vaccine given shortly before hepatitis B immune globulin, consider re-vaccination at least 3mo after hepatitis B immune globulin: combo may result in inadequate vaccine response (antagonistic effects)

  • immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + immune globulin

    vaccinate at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • influenza nasal vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    influenza nasal vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + influenza nasal vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • interferon beta 1a
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + interferon beta 1a

    consider vaccinating at least 4wk before or 3mo after interferon beta 1a tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • interferon beta 1b
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + interferon beta 1b

    consider vaccinating at least 4wk before or 3mo after interferon beta 1b tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • peginterferon beta 1a
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + peginterferon beta 1a

    consider vaccinating at least 4wk before or 3mo after peginterferon beta 1a tx or immunocompetence restored: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • rabies immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    rabies immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + rabies immune globulin

    vaccinate at least 2wk before or 4mo after rabies immune globulin tx; if vaccine given shortly before rabies immune globulin, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • Rho(D) immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    Rho(D) immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + Rho(D) immune globulin

    vaccinate at least 2wk before or 3mo after Rho(D) immune globulin tx; if vaccine given shortly before Rho(D) immune globulin, consider re-vaccination; do not delay postpartum vaccination in rubella or varicella susceptible patient, test for immunity in >3mo: combo may result in inadequate vaccine response (antagonistic effects)

  • smallpox vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    smallpox vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + smallpox vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • smallpox/mpox vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    smallpox/ mpox vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + smallpox/ mpox vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • tetanus immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tetanus immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + tetanus immune globulin

    vaccinate at least 2wk before or 3mo after tetanus immune globulin tx; if vaccine given shortly before tetanus immune globulin, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • tuberculin purified protein derivative
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    tuberculin purified protein derivative
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + tuberculin purified protein derivative

    admin. at same visit or at least 4-6wk apart: combo may interfere with test results (antagonistic effects)

  • vaccinia immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    vaccinia immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + vaccinia immune globulin

    vaccinate at least 2wk before or 3mo after vaccinia immune globulin tx; if vaccine given shortly before vaccinia immune globulin, consider re-vaccination at least 3mo after vaccinia immune globulin: combo may result in inadequate vaccine response (antagonistic effects)

  • varicella vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    varicella vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + varicella vaccine, live

    admin. at same visit or at least 4wk apart: combo may decr. response to 2nd vaccine if not administered together or >4wk apart (mechanism unknown)

  • varicella zoster immune globulin
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    varicella zoster immune globulin
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + varicella zoster immune globulin

    vaccinate at least 2wk before or 5 mo after varicella immune globulin tx; if vaccine given shortly before varicella immune globulin, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • yellow fever vaccine, live
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    yellow fever vaccine, live
    1 interaction

    Monitor/Modify Tx

    measles/ mumps/ rubella vaccine, live + yellow fever vaccine, live

    admin. at same visit or at least 30 days apart: combo may decr. response to 2nd vaccine if not administered together or >30 days apart (mechanism unknown)

Caution Advised

  • leniolisib
  • MMR II (measles/ mumps/ rubella vaccine, live (MMR))
    +
    leniolisib
    1 interaction

    Caution Advised

    measles/ mumps/ rubella vaccine, live + leniolisib

    caution advised: combo may result in inadequate vaccine response (immunomodulatory effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@47e3066d
  • anaphylaxis
  • hypersensitivity reaction
  • Henoch-Schonlein purpura
  • acute hemorrhagic edema of infancy
  • erythema multiforme
  • Stevens-Johnson syndrome
  • atypical measles
  • thrombocytopenia
  • seizures
  • febrile seizures
  • encephalopathy
  • encephalitis
  • Guillain-Barre syndrome
  • neurotoxicity
  • pneumonitis
  • pancreatitis

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@2956bf43
  • arthralgia
  • arthritis
  • fever
  • urticaria
  • rash
  • rash, measles-like
  • pruritus
  • injection site reaction
  • headache
  • dizziness
  • malaise
  • irritability

Safety/Monitoring .

Monitoring Parameters
no routine tests recommended

Look/Sound-Alike Drug Names
M-M-R II confused with: Meruvax II

Pregnancy/Lactation .

Pregnancy

Clinical Summary

contraindicated during pregnancy; delay vaccination until pregnancy completed; possible risk of congenital rubella syndrome based on limited human data with other measles/mumps/rubella vaccine

Individuals of Reproductive Potential

avoid pregnancy by using effective contraception x4wk after vaccination in patients of childbearing potential

Lactation

Clinical Summary

benefits outweigh risks while breastfeeding; inadequate human data available, though possible risk of mild infant rubella infection; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@39edbc71

Metabolism: for measles/mumps/rubella vaccine: other; CYP450: unknown

Excretion: for measles/mumps/rubella vaccine: other; Half-life: unknown

Subclass: Measles/Mumps/Rubella Vaccines ; Routine Adult Vaccines ; Routine Pediatric Vaccines ; Travel Vaccines

Mechanism of Action
for measles/mumps/rubella vaccine: exact mechanism of action unknown; induces antibody formation

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Merck & Co., Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@20a15fd1

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

subcutaneous powder for injection:

  • 0.5 mL (1 dose): $95.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information